Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study)

Table 2 Study Outline

Target number of patients: 408 patients
Study Design: Randomization	Aspirin group (81–100 mg/day; Group A) Cilostazol group (100–200 mg/day; Group C)
Follow-up: 2-year prospective follow-up study
Primary endpoints:
IMT*: Variation of right and left max IMT-CCA and mean IMT-CCA
Secondary endpoints:
IMT*: Variation of right and left max IMT-ICA

*Variation is measured by the IMT Evaluation Committee by using a diagnostic software application called IntimaScope^® while the allocations are blinded.

ISSN: 1475-2840